Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid

DC FieldValueLanguage
dc.contributor.authorMahmoudi, Souha-
dc.contributor.authorSamadi, Pershia-
dc.contributor.authorGilbert, François-
dc.contributor.authorOuattara, Bazoumana-
dc.contributor.authorMorissette, Marc-
dc.contributor.authorGrégoire, Laurent-
dc.contributor.authorRouillard, Claude-
dc.contributor.authorDi Paolo, Thérèse-
dc.contributor.authorLévesque, Daniel-
dc.date.accessioned2018-02-09T20:02:09Z-
dc.date.available2018-02-09T20:02:09Z-
dc.date.issued2009-07-25-
dc.identifier.issn0969-9961fr
dc.identifier.urihttp://hdl.handle.net/20.500.11794/16955-
dc.description.abstractWe have previously shown that docosahexaenoic acid (DHA) significantly reduced L-Dopa-induced dyskinesia (LID) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys (Samadi et al., Ann. Neurol. 59:282–288, 2006). In the present study, we measured for the first time mRNA levels of Nur77, an orphan nuclear receptor that participates to adaptive and/or aberrant dopamine-related behaviors, and retinoid X receptor γ1 (RXRγ1), a putative brain receptor for DHA and transcriptional partner of Nur77, in MPTP monkeys treated with L-Dopa and DHA. The RXRγ1 mRNA is strongly expressed in monkey caudate nucleus and putamen, but no change in levels of RXRγ1 was observed following MPTP and L-Dopa treatments. On the other hand, denervation reduced Nur77 mRNA levels, whereas chronic L-Dopa treatment strongly induced Nur77 transcripts. These modulations are taking place in substance P positive cells and are associated with both caudate-putamen matrix and striosome compartments. Interestingly, combination of L-Dopa with DHA further increases Nur77 mRNA levels in the anterior caudate-putamen, and mainly in striosomes. This is accompanied by a significant inverse correlation between Nur77 mRNA levels and dyskinetic scores. Taken together, our results show that Nur77 expression is modulated following dopamine denervation and chronic L-Dopa therapy in a non-human primate model of Parkinson's disease, and suggest that strong modulation of Nur77 expression might be linked to a reduced risk to develop LIDs.fr
dc.languageengfr
dc.publisherBlackwell Sciencefr
dc.subjectNGFI-Bfr
dc.subjectNR4A1fr
dc.subjectDHAfr
dc.subjectRetinoid X receptor (RXR)fr
dc.subjectMPTP-treated monkeyfr
dc.subjectParkinson’s diseasefr
dc.subjectL-Dopa-induced dyskinesia (LID)fr
dc.subjectSubstance Pfr
dc.subjectBasal gangliafr
dc.subjectCaudate nucleusfr
dc.subjectPutamenfr
dc.subjectStriatumfr
dc.titleNur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acidfr
dc.typeCOAR1_1::Texte::Périodique::Revue::Contribution à un journal::Article::Article de recherchefr
dcterms.bibliographicCitationNeurobiology of Disease, Vol. 36 (1), 213–222 (2009)fr
dc.identifier.doi10.1016/j.nbd.2009.07.017fr
dc.identifier.pubmedPMC4807127fr
dc.subject.rvmAcide docosahexaénoïquefr
dc.subject.rvmMéthylphényltétrahydropyridinefr
dc.subject.rvmARN messagerfr
dc.subject.rvmDyskinésiesfr
dc.subject.rvmRétinoïdesfr
dc.subject.rvmSinges (Animaux de laboratoire)fr
dc.subject.rvmNoyaux gris centrauxfr
dc.subject.rvmSubstance Pfr
dc.subject.rvmNoyau caudéfr
dc.subject.rvmPutamenfr
dc.subject.rvmCorps striéfr
dc.subject.rvmMaladie de Parkinsonfr
rioxxterms.versionAccepted Manuscriptfr
rioxxterms.version_of_recordhttps://doi.org/10.1016/j.nbd.2009.07.017fr
rioxxterms.project.funder_nameCanadian Institutes of Health Researchfr
rioxxterms.project.funder_nameParkinson Society Canadafr
rioxxterms.project.funder_nameParkinson’s Disease Foundationfr
bul.rights.periodeEmbargo12 moisfr
dc.audience.peerreviewOuifr
Collection:Articles publiés dans des revues avec comité de lecture

Files in this item:
Description SizeFormat 
nihms5154.pdf1.37 MBAdobe PDFThumbnail
View/Open
All documents in CorpusUL are protected by Copyright Act of Canada.